Pfizer plans to pull leukemia drug Mylotarg from U.S. market

06/21/2010 | Reuters

Pfizer will voluntarily take Mylotarg off the U.S. market Oct. 15 after the injectable drug failed to show efficacy during a study when given in combination with chemotherapy to patients with acute myeloid leukemia. The decision follows the FDA's recommendation to withdraw the product because of safety concerns and lack of clinical benefit.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA